A&A practice

Ovid Technologies (Wolters Kluwer Health)
Ovid Technologies (Wolters Kluwer Health)
ISSN: 25753126

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q4
WOS
Q4
Impact factor
0.5
SJR
0.239
CiteScore
1.4
Categories
Medicine (miscellaneous)
Areas
Medicine
Years of issue
2018-2025
journal names
A&A practice
A A PRACT
Publications
1 290
Citations
2 960
h-index
18
Top-3 citing journals
A&A practice
A&A practice (175 citations)
Cureus
Cureus (97 citations)
Top-3 organizations
Harvard University
Harvard University (18 publications)
Massachusetts General Hospital
Massachusetts General Hospital (13 publications)
Mayo Clinic
Mayo Clinic (13 publications)
Top-3 countries
USA (321 publications)
India (36 publications)
Japan (34 publications)

Most cited in 5 years

Found 
from chars
Publications found: 900
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E
Lozupone M., Dibello V., Daniele A., Panza F.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder
Carnero Contentti E., Correale J.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging treatments for sarcoma: from 2024 onward
Gómez-Puerto D., Cicala C.M., Valverde C., Serrano C.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging biological treatments for asthma
Pastore D., Lupia C., D’Amato M., Bruni A., Garofalo E., Longhini F., Gallelli L., Vatrella A., Pelaia G., Pelaia C.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Mitapivat: a step forward across different hemolytic diseases
Hodroj M.H., Klim J., Charbel N., Taher A.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
FcRn inhibitors in the context of myasthenia gravis
Menon D., Bhandari V.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?
Harvey P.D.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma
Mok K., Chen O., Yau J., Chan L.L., Chan S.L.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Seltorexant for major depressive disorder
Valentino K., Teopiz K.M., Wong S., Zhang M.C., Le G.H., Choi H., Ballum H., Dri C., Cheung W., McIntyre R.S.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Exploring emerging JAK inhibitors in the treatment of aicardi-goutières syndrome
Politano D., Tonduti D., Battini R., Fazzi E., Orcesi S.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis
Patel H.A., Tran L., Karagenova R., Feldman S.R.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?
Hansford J.R., Manoharan N., Bouche G., Ramaswamy V., Jabado N., Bouffet E.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results
Stella L., Hollande C., Merabet Y.B., Fakhouri H., Leclerc V., Ponziani F.R., Bouattour M.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion
Pan L., Nagib L., Ganguly S., Moorthy A., Tahir H.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 1
Current and emerging drug treatment strategies to tackle sickle cell anemia
Persaud Y., Leonard A., Rai P.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0

Top-100

Citing journals

20
40
60
80
100
120
140
160
180
Show all (70 more)
20
40
60
80
100
120
140
160
180

Citing publishers

100
200
300
400
500
600
Show all (70 more)
100
200
300
400
500
600

Publishing organizations

2
4
6
8
10
12
14
16
18
Show all (70 more)
2
4
6
8
10
12
14
16
18

Publishing organizations in 5 years

2
4
6
8
10
12
14
16
Show all (70 more)
2
4
6
8
10
12
14
16

Publishing countries

50
100
150
200
250
300
350
USA, 321, 24.88%
India, 36, 2.79%
Japan, 34, 2.64%
Canada, 22, 1.71%
United Kingdom, 8, 0.62%
Turkey, 8, 0.62%
Belgium, 7, 0.54%
Switzerland, 7, 0.54%
Israel, 6, 0.47%
Germany, 5, 0.39%
France, 5, 0.39%
China, 4, 0.31%
Australia, 4, 0.31%
Denmark, 4, 0.31%
Mexico, 4, 0.31%
Portugal, 3, 0.23%
Spain, 3, 0.23%
Netherlands, 3, 0.23%
New Zealand, 3, 0.23%
Republic of Korea, 3, 0.23%
Singapore, 3, 0.23%
Argentina, 2, 0.16%
Brazil, 2, 0.16%
Colombia, 2, 0.16%
Costa Rica, 2, 0.16%
Norway, 2, 0.16%
Guatemala, 1, 0.08%
Greece, 1, 0.08%
Egypt, 1, 0.08%
Jordan, 1, 0.08%
Iran, 1, 0.08%
Ireland, 1, 0.08%
Italy, 1, 0.08%
Lebanon, 1, 0.08%
Malaysia, 1, 0.08%
UAE, 1, 0.08%
Oman, 1, 0.08%
Saudi Arabia, 1, 0.08%
Slovenia, 1, 0.08%
Tunisia, 1, 0.08%
Croatia, 1, 0.08%
Sweden, 1, 0.08%
Sri Lanka, 1, 0.08%
Show all (13 more)
50
100
150
200
250
300
350

Publishing countries in 5 years

50
100
150
200
250
USA, 216, 29.31%
India, 28, 3.8%
Japan, 23, 3.12%
Canada, 11, 1.49%
Turkey, 7, 0.95%
Germany, 5, 0.68%
Belgium, 5, 0.68%
Switzerland, 5, 0.68%
United Kingdom, 4, 0.54%
Israel, 4, 0.54%
France, 3, 0.41%
Denmark, 3, 0.41%
Mexico, 3, 0.41%
Netherlands, 3, 0.41%
Republic of Korea, 3, 0.41%
China, 2, 0.27%
Portugal, 2, 0.27%
Brazil, 2, 0.27%
Spain, 2, 0.27%
Colombia, 2, 0.27%
Costa Rica, 2, 0.27%
New Zealand, 2, 0.27%
Singapore, 2, 0.27%
Australia, 1, 0.14%
Argentina, 1, 0.14%
Egypt, 1, 0.14%
Jordan, 1, 0.14%
Ireland, 1, 0.14%
Italy, 1, 0.14%
Lebanon, 1, 0.14%
Malaysia, 1, 0.14%
Norway, 1, 0.14%
UAE, 1, 0.14%
Oman, 1, 0.14%
Saudi Arabia, 1, 0.14%
Slovenia, 1, 0.14%
Sweden, 1, 0.14%
Sri Lanka, 1, 0.14%
Show all (8 more)
50
100
150
200
250